XDx, a molecular diagnostics company, today announced its AlloMap® molecular expression test will be the subject of presentations and discussions at the American Transplant Congress 2007.

The test, currently used to detect the absence of heart transplant rejection instead of routine invasive heart muscle biopsies, has now been shown to correlate with oxygen saturation levels, cardiac filling pressures, and the electrical properties of the transplanted heart.

Also, data from the Lung Allograft Rejection Gene expression Observation (LARGO) study presented at the ATC sessions demonstrate that a non-invasive blood test can detect cytomegalovirus-induced immune responses in lung transplant patients.

Researchers at the University of California, San Diego (UCSD) School of Medicine have developed new technology which, combined with proteomics – the large-scale study of the structure and function of proteins and their functions – has allowed them to map an extensive network of the signaling proteins that control cell movement.

Their work, providing the first comprehensive profile of cell movement, could lead to a better understanding of cell migration in cancer metastasis and inflammatory disease.

Researchers at the Department of Energy's Argonne National Laboratory have developed a new approach to increasing the capacity and stability of rechargeable lithium-ion batteries.

The technology is based on a new material for the positive electrode that is comprised of a unique nano-crystalline, layered-composite structure.

A new study showed that a certain form of neuropsin, a protein that plays a role in learning and memory, is expressed only in the central nervous systems of humans and that it originated less than five million years ago.

The human and chimpanzee genomes vary by just 1.2 percent, yet there is a considerable difference in the mental and linguistic capabilities between the two species.

The likelihood of developing bipolar disorder depends in part on the combined, small effects of variations in many different genes in the brain, none of which is powerful enough to cause the disease by itself, a new study shows.

However, targeting the enzyme produced by one of these genes could lead to development of new, more effective medications. The research was conducted by scientists at the National Institutes of Health's National Institute of Mental Health (NIMH), with others from the Universities of Heidelberg and Bonn and a number of U.S. facilities collaborating in a major project called the NIMH Genetics Initiative.

The study is the first to scan virtually all of the variations in human genes to find those associated with bipolar disorder.

The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25% of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient’s HER2 status.

The challenge is to develop a testing strategy that is both accurate and economical. A false-negative test result can mean a woman will not receive a life-prolonging drug, and a false-positive result can lead to unnecessary, expensive drug treatment.